Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Subfoveal Choroidal Neovascularization (CNV)Secondary to Age-related Macular Degeneration (AMD)
Interventions
DRUG

ranibizumab

Trial Locations (36)

Unknown

Novartis Investigational Site, Melbourne

Novartis Investigative Site, Laken

Novartis Investigative Site, Leuven

Novartis Investigative Site, Liège

Novartis Investigative Site, Berlin

Novartis Investigative Site, Bonn

Novartis Investigative Site, Bremen

Novartis Investigative Site, Chemnitz

Novartis Investigative Site, Cologne

Novartis Investigative Site, Düsseldorf

Novartis Investigative Site, Kiel

Novartis Investigative Site, Leipzig

Novartis Investigative Site, Marburg

Novartis Investigative Site, München

Novartis Investigative Site, Siegburg

Novartis Investigative Site, Tübingen

Novartis Investigative Site, Würzburg

Novartis Investigative Site, Budapest

Novartis Investigative Site, Debrecen

Novartis Investigative Site, Petah Tikva

Novartis Investigative Site, Tel Aviv

Novartis Investigative Site, Tel Litwinsky

Novartis Investigative Site, Amsterdam

Novartis Investigative Site, Nijmegen

Novartis Investigative Site, Coimbra

Novartis Investigative Site, Porto

Novartis Investigative Site, Alicante

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Madrid

Novartis Investigative Site, Santiago de Compostela

Novartis Investigative Site, Valencia

Novartis Investigative SIte, Ankara

Novartis Investigative Site, Bristol

Novartis Investigative Site, Southampton

Novartis Investigative Site, West Midlands

Novartis Investigative Site, Wolverhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY